Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer

Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer

Heparanase (HPSE) is the dominant mammalian endoglycosidase and important tumorigenic, angiogenic, and pro-metastatic molecule. Highest levels of HPSE activity have been consistently detected in cells possessing highest propensities to colonize the brain, emphasizing the therapeutic potential for ta...

Full description

Bibliographic Details
Main Authors:	Lixin Zhang, Jason A. Ngo, Michael D. Wetzel, Dario Marchetti
Format:	Article
Language:	English
Published:	Elsevier 2015-01-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558614001882

Similar Items

Patient with metastatic breast cancer, HER2-positive, trastuzumab- and pertuzumab-resistant responding to lapatinib
by: Daniela Cianniello, et al.
Published: (2018-06-01)

ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer
by: Geneviève Deblois, et al.
Published: (2016-07-01)

Efficacy of Lapatinib in Therapy-Resistant HER2-Positive Circulating Tumor Cells in Metastatic Breast Cancer.
by: Sofia Agelaki, et al.
Published: (2015-01-01)

Antisense-Mediated Suppression of Heparanase Gene Inhibits Melanoma Cell Invasion
by: Madhuchhanda Roy, et al.
Published: (2005-03-01)

Association between efficacy and skin rash following treatment with the lapatinib in metastatic breast cancer
by: Suleyman Temiz, et al.
Published: (2016-04-01)

Response and resistance to lapatinib in HER2-overexpressing breast cancer
by: Leung, W
Published: (2014)

Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer
by: Shengnan Bao, et al.
Published: (2020-09-01)

Adipocyte-conditioned medium induces resistance of breast cancer cells to lapatinib
by: A. Geneste, et al.
Published: (2020-08-01)

Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib
by: John D. Strickley, et al.
Published: (2018-08-01)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
by: Min Ye, et al.
Published: (2021-07-01)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
by: Thibaut Sanglier, et al.
Published: (2023-06-01)

Lapatinib? or Radiotherapy? In Cranial Metastasis of Breast Cancer
by: Yasemin Benderli Cihan
Published: (2019-07-01)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
by: Punam Rana, et al.
Published: (2012-03-01)

Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer
by: Punam Rana, et al.
Published: (2012-01-01)

Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study
by: Yijia Hua, et al.
Published: (2022-03-01)

HER2-positive breast cancer with brain metastasis, long responder to lapatinib therapy
by: Chiara Saggia
Published: (2018-06-01)

Structural investigations on mechanism of lapatinib resistance caused by HER-2 mutants.
by: Sharad Verma, et al.
Published: (2018-01-01)

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer.
by: J Robert McCorkle, et al.
Published: (2021-01-01)

Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
by: J. Robert McCorkle, et al.
Published: (2021-01-01)

Erratum to: Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer
by: Azeem Saleem, et al.
Published: (2017-09-01)

Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.
by: Stefania Gori, et al.
Published: (2016-01-01)

The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
by: D. J Ouyang, et al.
Published: (2021-08-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Targeting HER 1 and 2 in breast cancer with lapatinib
by: Gerald M. Higa
Published: (2011-12-01)

Lapatinib for the treatment of HER2-overexpressing breast cancer
by: J Jones, et al.
Published: (2009-10-01)

Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals
by: Jun Wang, et al.
Published: (2020-01-01)

HSP90 Inhibitor, 17-DMAG, Alone and in Combination with Lapatinib Attenuates Acquired Lapatinib-Resistance in ER-positive, HER2-Overexpressing Breast Cancer Cell Line
by: Hye Jin Lee, et al.
Published: (2020-09-01)

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea
by: Ro Jungsil, et al.
Published: (2012-07-01)

HER2-positive breast cancer with brain metastasis: long-lasting response after lapatinib treatment
by: Alessia D'Alonzo, et al.
Published: (2018-06-01)

Dual targeting micelles loaded with paclitaxel and lapatinib for combinational therapy of brain metastases from breast cancer
by: Heng Lu, et al.
Published: (2022-02-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

In silico investigation of heparanase-correlated genes in breast cancer subtypes
by: Carina Mucciolo Melo, et al.
Published: (2020-10-01)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
by: Lanqi Ren, et al.
Published: (2023-08-01)

Long-term survival in a patient with metastatic HER2+ breast cancer undergoing lapatinib-based therapy for 6 years
by: Salvatore Turano, et al.
Published: (2018-09-01)

Systemic control and encephalic response with lapatinib plus capecitabine as second-line therapy in HER2-positive, metastatic breast cancer
by: Raffaele Ardito, et al.
Published: (2018-09-01)

Heparanase: A Novel Therapeutic Target for the Treatment of Atherosclerosis
by: Tien K. Nguyen, et al.
Published: (2022-10-01)

Feedback Activation of STAT3 Confers Resistance of HER2-positive Breast Cancer Cells to Lapatinib
by: HU Xiaohong, et al.
Published: (2019-04-01)

Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer
by: Bülent Karagöz, et al.
Published: (2015-01-01)

Dual HER2 Suppression with Lapatinib plus Trastuzumab for Metastatic Inflammatory Breast Cancer: A Case Report of Prolonged Stable Disease
by: Lauren Ogawa, et al.
Published: (2018-12-01)

Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
by: Machado M, et al.
Published: (2012-11-01)